NASDAQ:XLO Xilio Therapeutics Q1 2025 Earnings Results & Report $7.80 -0.44 (-5.28%) As of 12:34 PM Eastern This is a fair market value price provided by Massive. Learn more. Xilio Therapeutics missed analyst expectations on both earnings and revenue in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$2.52 versus the $1.40 consensus estimate, while revenue of $2.93 million fell short of the $42 million estimate by $39.07 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 13, 2025TimeBefore Market OpensConference Call DateMay 7, 2025Conference Call6:00 PM ET Xilio Therapeutics EPS ResultsActual EPS-$2.52Consensus EPS $1.40Beat/MissMissed by -$3.92One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersXilio Therapeutics Revenue ResultsActual Revenue$2.93 millionExpected Revenue$42 millionBeat/MissMissed by -$39.07 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Xilio Therapeutics Q1 2025 Earnings FAQ Did Xilio Therapeutics beat earnings estimates for Q1 2025? Xilio Therapeutics (NASDAQ:XLO) reported earnings of -$2.52 per share for Q1 2025, missing the consensus estimate of $1.40. The report was announced on Tuesday, May 13, 2025. What was Xilio Therapeutics' revenue for Q1 2025? Xilio Therapeutics reported revenue of $2.93 million for Q1 2025, against a consensus estimate of $42 million. Xilio Therapeutics Earnings HeadlinesXilio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 11 at 9:56 AM | marketscreener.comMXilio Doses First Patient In XTX501 Cancer Trial; Plans 2027 Data ReadoutNovember 10 at 2:46 PM | rttnews.comGOP wipeout … but here's WORSE news for the marketA 3 trillion dollar crisis may be building beneath the surface of the stock market, retirement accounts, pensions, and even banks. Reuters reports alarm bells echoing 2007 subprime warnings, and bestselling author Dr. Martin Weiss says this one may already be underway. His free briefing outlines five steps investors are considering to help protect their portfolios.November 13 at 1:00 AM | Weiss Ratings (Ad)Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesNovember 10 at 7:30 AM | globenewswire.comXilio Therapeutics (XLO) Projected to Announce Quarterly Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comXilio Therapeutics (NASDAQ:XLO) Stock Price Breaks Above Two Hundred Day Moving Average - Here's WhyNovember 4, 2026 | americanbankingnews.comSee More Xilio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xilio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xilio Therapeutics and other key companies, straight to your email. Email Address About Xilio TherapeuticsXilio Therapeutics (NASDAQ:XLO) is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects. Xilio’s research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments. Its pipeline is intended to stimulate immune responses within solid tumors and potentially address cancers that have limited responses to existing immunotherapies. The company’s programs remain in clinical development and are subject to the risks and uncertainties associated with biotechnology research. Founded in 2020 and headquartered in Waltham, Massachusetts, Xilio Therapeutics serves the global oncology market through its drug-discovery and clinical-development activities. The company became publicly traded on the Nasdaq under the symbol XLO in 2021. Xilio is led by René Russo, who serves as president and chief executive officer.View Xilio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
